Table 3.

Overview on clinical studies using the combination of paritaprevir/ritonavir + ombitasvir ± dasabuvir

Study	Patient population	Therapy	Duration (wk)	SVR	Comments
SAPPHIRE-I	First-line therapy	OBV + PTV/r + DSV + R	12	96%	No cirrhosis
SAPPHIRE-II	Re-therapy	OBV + PTV/r + DSV + R	12	96%	No cirrhosis
TURQUOISE-II	Cirrhosis	OBV + PTV/r + DSV + R	12	92%	GT1a 89%
					GT1b 99%
		OBV + PTV/r + DSV + R	24	96%	GT1a 95%
					GT1b 100%
PEARL-II	Re-therapy, GT1b	OBV + PTV/r + DSV	12	100%	No cirrhosis
		OBV + PTV/r + DSV + R	12	97%	No cirrhosis
PEARL-III	First-line therapy, GT1b	OBV + PTV/r + DSV	12	99%	No cirrhosis
		OBV + PTV/r + DSV + R	12	99%	No cirrhosis
PEARL-IV	First-line therapy, GT1a	OBV + PTV/r + DSV	12	90%	No cirrhosis
		OBV + PTV/r + DSV + R	12	97%	No cirrhosis

OBV: Ombitasvir; PTV: Paritaprevir; DSV: Dasabuvir; R: Ribavirin; r: Ritonavir; SVR: Sustained virological response.